Tesamorelin vs MK-677: Two Very Different Ways to Raise GH (2026)

Tesamorelin and MK-677 get compared constantly because they share a headline — both raise growth hormone — but the comparison is genuinely apples-to-oranges in almost every way that matters. One is an injectable peptide acting on the GHRH receptor; the other is an orally active small molecule acting on the ghrelin receptor. They are not two versions of the same idea. This is a research-use comparison of how they differ in chemistry, mechanism, format, and evidence base. Nothing here is dosing or supplementation guidance.

The fundamental split: peptide vs small molecule

The first thing to get straight is that these compounds are different kinds of molecule entirely.

Tesamorelin is a peptide — a 44-residue analog of growth-hormone-releasing hormone (GHRH), identical to human GHRH(1-44) except for a trans-3-hexenoyl cap on the N-terminus that protects it from rapid enzymatic degradation. Like all peptides of this size, it is degraded in the gut and is administered by injection.

MK-677 (ibutamoren) is a non-peptide small molecule — a spiropiperidine ghrelin-receptor agonist. It was deliberately designed to be orally bioavailable, surviving digestion to produce a sustained signal at the ghrelin receptor. That is the entire reason it exists as a distinct tool: an oral secretagogue, where the peptide options require a needle.

Property	Tesamorelin	MK-677 (ibutamoren)
Molecule type	Peptide (44 residues + acyl cap)	Non-peptide small molecule
Receptor target	GHRH receptor (pituitary)	Ghrelin receptor (GHS-R1a)
Pathway	GHRH / cAMP arm	Ghrelin / phospholipase-C arm
Format	Injectable	Orally active
Half-life character	Stabilized for once-daily injection	Long-acting, sustained signal
Regulatory status (US)	FDA-approved (Egrifta), one indication	Investigational, not approved

Different receptors, same endpoint

Both compounds drive growth-hormone release, but through two distinct receptor systems — and that distinction is the mechanistic core of the comparison.

Tesamorelin binds the GHRH receptor on the anterior pituitary, the same receptor native GHRH uses. It does not supply GH directly; it prompts the pituitary to synthesize and release the body's own GH in a pulsatile pattern, leaving native feedback loops (somatostatin, IGF-1) intact.

MK-677 acts on the ghrelin receptor (GHS-R1a) — the same receptor the peptide GHRPs like ipamorelin use. It is, functionally, a small-molecule ghrelin mimetic. A notable consequence of its long-acting GHS-R1a agonism is a more sustained elevation of the GH/IGF-1 axis than a short pulse produces.

Because the two receptors are independent pathways, GHRH-pathway and ghrelin-pathway compounds are often studied in combination rather than as substitutes — they can complement rather than simply duplicate each other. Our GHRP vs GHRH explainer maps the two receptor systems, and the growth-hormone secretagogue mechanisms piece goes down to the second-messenger level.

Evidence base: a sharp asymmetry

This is where the two diverge most outside the lab. Tesamorelin carries a registrational clinical dataset — it advanced through Phase III trials and earned FDA approval in 2010 for HIV-associated lipodystrophy, with published research extending into visceral and liver fat and exploratory cognitive endpoints. That is an unusually deep evidence base for a compound in this space.

MK-677 has been studied in clinical research over a long period — including work on the GH/IGF-1 axis, body composition, and sleep-related endpoints in various populations — but it has not achieved approval for any indication. Its literature is real and substantial, but it remains an investigational compound. The honest framing: one compound has a registered identity for a narrow use, the other is a well-studied investigational molecule, and neither status licenses off-label or research-chemical human use.

Format drives how each is studied

The injectable-vs-oral split is not a trivial convenience difference; it shapes the research itself.

• Tesamorelin's injectable, once-daily, stabilized profile suits research modeling a controlled pulsatile GHRH signal — the design intent of the molecule.
• MK-677's oral, long-acting profile produces a more continuous elevation of the axis, which is a different pharmacodynamic shape and is studied accordingly.

That difference in signal shape — pulsatile peptide vs sustained small molecule — is arguably as important as the receptor difference, because the GH axis responds differently to pulses than to tonic stimulation, and chronic continuous agonism raises the desensitization questions covered in the mechanism literature.

Sourcing and verification

Only tesamorelin is in our verified catalog; MK-677 is not, so for MK-677 this remains a literature comparison, not a sourcing guide. Tesamorelin's verification bar reflects its size:

Marker	What to look for
HPLC purity	≥98% by reversed-phase HPLC, batch-specific
Mass spec	Observed mass ~5136 Da, confirming the hexenoyl-modified 44-mer
Third-party testing	Independent lab (Janoshik, MZ Biolabs, or equivalent)
Cold chain	Refrigerated transit for a large peptide
Documentation	Batch-specific COA tied to your lot

A 44-residue peptide with a non-standard acyl cap is harder to synthesize cleanly than a short peptide, which makes a clean chromatogram and mass-spec confirmation genuinely informative. For the verified compound, see the peptide reference library, the growth-hormone research goal, and our where-to-buy guidance. For the paperwork, see our guide to reading a peptide COA.

Bottom line

Tesamorelin and MK-677 share a headline and almost nothing else. Tesamorelin is an injectable GHRH-analog peptide with FDA approval for one indication and a deep clinical record, working on the pituitary GHRH receptor with a pulsatile signal. MK-677 is an orally active, non-peptide ghrelin-receptor agonist — investigational, not approved — producing a sustained signal on a different pathway. Calling them alternatives flattens a real distinction in molecule type, receptor, format, and evidence. Reason at the compound level: the endpoint is shared, but the tools are not.

For research use only. Research-grade material is not an approved drug, and neither compound is for human consumption.

2026 Evaluation

9.6/10

Top-Ranked 2026 Supplier

The top-ranked supplier in our 2026 evaluation

ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.

View ROEHN Research→

Save 15% with code FREE15

• Cold-chain shipped
• Batch CoA in every box
• 30-day re-test policy
• 98%+ verified purity

---

Disclosure: Peptide Research Review maintains affiliate relationships with some of the suppliers we reference. Affiliate status has no influence on our research framing or our blinded, third-party lab evaluations. Read our editorial policy and methodology.